Specialty pharmacy updates - June 2022

Specialty pharmacy updates for Anthem are listed below.

 

Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by Anthem’s medical specialty drug review team. Review of specialty pharmacy drugs for oncology use is managed by AIM Specialty Health^® (AIM), a separate company.

 

Important to note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request prior authorization review for your patients’ continued use of these medications.

 

Inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a not otherwise classified (NOC) code.

 

Prior authorization updates

Effective for dates of service on and after September 1, 2022, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process.

 

Access our clinical criteria to view the complete information for these prior authorization updates.

 

Clinical Criteria	Drug	HCPCS or CPT Code(s)
ING-CC-0214+	Carvykti (ciltacabtagene autoleucel)	C9399, J3490, J3590
ING-CC-0200+	Aduhelm (aducanumab-avwa)	J0172

+The applicable policy is attached to this article in PDF format.

 

Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity.

 

2738-0622-PN-ME